4Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China).不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究[J].中华心血管病杂志,2000,28(1):18-21. 被引量：172
1Sayre MR, Kaufmann KH, Chen IW et al. Measurement of cardiac troponin T ia an effective method for predicting complications among emergenoy department patients with chest pain. Ann Emerg Med 1998;31:539- 49
2Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973 - 9
3Ridker N, Rifai N, Pfeffer MA et al. Long - term effects of pravastatin on plasma concentration of CRP. CARE Investigators. Circulation 1999; 100:230 - 5
5The FRAXIS Study Group. Comparison of two treatment durations ( 6 days and 14 days) of a low molecular weight heparin with a 6 - day treatment of unfractionated heparin in the initial management of unstable angina or non- Q wave myocardial infarction: FRAX. I. S. (FRAxiparin in Ischemic Syndrome) .Eur Heart J 1999;20:1553 - 1562
6Antman EM, Cohen M, Radley D, et al. Enoxaparin for unstable angina/ non- Q wave myocardial infarction: Meta- analysis of TIMI- l1B and ESSENCE.J Am Coll Cardiol 1999;33(Suppl A):351(Abstr 819- 1)
7The EPILOG Investigators. Platelet glycoprotein Ⅰb/Ⅲa receptor blockade and low- dose heparin during percutaneous coronary revascularizatiort. N Engl J Med 1997;336:1689 - 96
8The PRISM - PLUS Investigators. Inhibition of platelet glycoprotein Ⅱb/ Ⅲa receptor with tirofiban in unstable angina and non - Q wave myocardial infarction. N Engl J Med 1998;338: 1488- 97
9CAPTURE Investigators. Randomized placebo- controlled trial of abciximab befor and during coronary intervention in refractory angina:the CAPTURE study. Lancet 1997; 349: 1429 - 34
10The Fragmin and Fast Revascularization during Instability in Coronary artery disease (FRISC Ⅱ) Investigators. Invasive compared with noninvasive treatment in unstable coronary artery disease: FRISC 11 prospective randomized multicenter study. Lancet 1999; 354: 708 - 715
1McCarty M F.Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1,a mediator of the IL-6 signal transduction pathway[J].Med Hypotheses,2003,60(5):634-639.
2Musial J,Undas A,Gajewski P,et al.Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia[J].Int J Cardiol,2001,77(2/3):247-253.
3Braunwald E,Antman E M,Beasley J W,et al.ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction.A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina)[J].J Am Coll Cardiol,2002,40(7):1366-1374.
4Kinlay S,Rifai N,Libby P,et al.Effect of atorvastatin on C-reactive protein in patients with acute coronary syndrome:a substudy of the MIRACL trial [J].J Am Coll Cardiol,2008(5):107-110.
5Yamaoka-Tojo M,Tojo T,Masuda T,et al.C-reactive protein-induced production of interleukin-18 in human endothelial cells:a mechanism of orchestrating cytokine cascade in acute coronary syndrome[J].Heart Vessels,2003,18(4):183-187.
